See Editorial on Page 1795
Autoimmune, Cholestatic and Biliary Disease
Article first published online: 8 FEB 2009
Copyright © 2009 American Association for the Study of Liver Diseases
Volume 49, Issue 6, pages 1972–1981, June 2009
How to Cite
Halilbasic, E., Fiorotto, R., Fickert, P., Marschall, H.-U., Moustafa, T., Spirli, C., Fuchsbichler, A., Gumhold, J., Silbert, D., Zatloukal, K., Langner, C., Maitra, U., Denk, H., Hofmann, A. F., Strazzabosco, M. and Trauner, M. (2009), Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice. Hepatology, 49: 1972–1981. doi: 10.1002/hep.22891
Potential conflict of interest: Nothing to report.
The Medical University of Graz has filed the patent for the use of norUDCA in the treatment of liver diseases, and Michael Trauner, Alan Hofmann, and Peter Fickert are listed as inventors (publication number WO2006119803).
- Issue published online: 28 MAY 2009
- Article first published online: 8 FEB 2009
- Accepted manuscript online: 8 FEB 2009 12:00AM EST
- Manuscript Accepted: 26 JAN 2009
- Manuscript Received: 18 SEP 2008
- Austrian Science Foundation. Grant Number: P19118-B05
- GEN-AU project. Grant Number: GZ 200.139/1-VI/1/2006
- Austrian Ministry for Science
- Swedish Research Council
- The Swedish Medical Association
- Ph.D. program of the Medical University of Graz
- Fondazione S. Martino, Bergamo
- National Institutes of Health. Grant Numbers: DK079005, DK64891
- Yale University Liver Center (National Institutes of Health). Grant Number: DK34989
- Cystic Fibrosis Foundation. Grant Number: CFF-FIOROT0810
- ALF/AASLD Liver Scholar Award
- JNCASR, Bangalore
Additional Supporting Information may be found in the online version of this article.
|HEP_22891_sm_SupFig1.tif||722K||Supplementary Figure S1. Structures of norUDCA, tauro-norUDCA and dinorUDCA. Nor-ursodeoxycholic acid (norUDCA) results from side chain-shortening of ursodeoxycholic acid (UDCA) by one methyl group. Side chain shortening of norUDCA by another methyl group results in dinorursodeoxycholic acid (dinorUDCA). Tauro-norursodeoxycholic acid (T-norUDCA) was obtained by taurine-conjugation of norUDCA.|
|HEP_22891_sm_SupFig2.tif||23240K||Supplementary Figure S2. NorUDCA is more effective than tauro-norUDCA and dinorUDCA in reducing sclerosing cholangitis and biliary fibrosis in Mdr2-/- mice. Liver histology (H&E staining) in standard chow-fed (Control), norUDCA-fed, tauro-norUDCA-fed (T-norUDCA), and dinorUDCA-fed Mdr2-/- mouse (original magnification 20x). Compared to striking reduction of bile duct injury in norUDCA-treated Mdr2-/- mouse, the effects of tauro-norUDCA are much weaker. DinorUDCA had no influence on large bile duct injury. bd, bile duct; pv, portal vein.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.